BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

3 Safe Vanguard ETFs Paying Dividends in Volatile Markets

Fund Managers Analyze Market Correction: Risk Aversion Dominates, Advise Holding Shares Through Holiday and Waiting for Recovery

Stock vs Index Volatility Divergence! Hot US Equity Trade: Long Single-Stock Options, Hedge with Index Options

These Two Market Gauges May Signal a Big Risk-Off Event for the Market, Says BofA

Market Chatter: Federal Reserve Mulls Raising Bank Oversight Thresholds

Traders Place Record Bets Against Oil as Brent Options Surge and Peace Talks Advance

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Gundlach warns next US recession could trigger a fiscal crunch as bond haven status fades

Korean Won Extends Losing Streak to Fourth Session Amid Fed's Hawkish Stance and Risk Aversion

Why Archer and Joby Stocks Are Falling as Oil and Treasury Yields Rise

AstraZeneca’s ATTR-CM Imaging Sub-study Wraps Up, Setting the Stage for New Data Insights

Bond Yields at 5%, Oil at $120, VIX at 25? The Market's Nightmare Scenario Is Rapidly Becoming Reality

Intercont says not commenting on short-term market volatility

Capital Markets Warns of Rising Odds for a U.S. Stock Correction, Citing Midterm Election Risks and AI Trade Instability

Wall Street's Deceptive Calm Meets Bond Market's Stern Warning: As VIX Falls Silent, Are Treasury Yields the New Fear Barometer for Equities?

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study